Noxopharm (ASX:NOX) has announced that data involving its Sofra assets will be highlighted at a major international conference later this year.
The material will be presented by CSL at the Options for the Control of Influenza XIII Conference in August in Washington, DC, and will relate to how Noxopharm’s novel oligonucleotides from its Sofra technology platform could be used to improve the delivery of self-amplifying mRNA vaccines.
Sofra comprises a novel class of drugs designed to precisely regulate innate immune signalling and to target inflammatory and autoimmune diseases as well as RNA therapeutics and vaccines. The platform has potential applications across a wide range of immune-related conditions, such as rheumatoid arthritis, lupus, and diabetes, as well as in oncology and for off-target effects of RNA therapeutics.
The Options conference is the largest global scientific meeting focused on influenza prevention, control and treatment, bringing together leading experts in virology, clinical care, public health and vaccine research to share evidence and foster collaboration.
Noxopharm CEO Dr Olivier Laczka said, “The Sofra platform could be used in many areas where inflammation plays a role, and we have made significant progress bringing it to a point where it is attracting attention not only because of its versatility, but also because of the breakthrough understanding of the immune system on which it is based.”